GLP-1 medications and gallbladder disease: what 1,829 real cases reveal

TL;DR

An analysis of the FDA Adverse Event Reporting System (FAERS) database identified 1,829 reports of gallbladder disease linked to GLP-1 medications across 20 years of data. All five major GLP-1 drugs showed a positive signal. Liraglutide had the strongest association, tirzepatide had the fastest onset at 80 days, and 92% of reported cases were classified as serious. Women aged 45-64 were the most affected group.

Gallbladder problems are on the label for GLP-1 medications. Most prescribing information mentions increased gallstone risk. But the specifics - which drugs carry the highest risk, how quickly problems develop, and how serious they tend to be - have not been well quantified until now. A study published in Frontiers in Pharmacology in July 2025 digs into the real-world data.

What is FAERS and why does it matter?

The FDA Adverse Event Reporting System is a database where healthcare professionals, manufacturers, and patients submit reports of adverse events - side effects and problems associated with approved drugs. It is not a perfect system: reporting is voluntary, not all events get reported, and FAERS data cannot prove causation. But pharmacovigilance analysis of FAERS is a standard tool for detecting real-world signals that clinical trials may miss, particularly for rare or delayed adverse effects.

The study, led by Chao Tao and colleagues, analysed FAERS data from the first quarter of 2004 through the second quarter of 2024. They applied three independent statistical methods - reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) - to confirm that any signal they identified was robust rather than a statistical artefact.

The scale of the problem: 1,829 reports across five drugs

The researchers identified 1,651 unique patients with 1,829 adverse event reports where a GLP-1 receptor agonist was the primary suspect drug. The breakdown by drug:

• Exenatide: 506 reports
• Liraglutide: 491 reports
• Semaglutide: 473 reports
• Dulaglutide: 189 reports
• Tirzepatide: 159 reports

The patient demographics paint a consistent picture: 58.7% were female, with the 45-64 age group accounting for 33.8% of all cases. This tracks with what we know about gallstone risk factors independently - women, particularly post-menopausal women, and people over 40 are the highest-risk groups for gallbladder disease. GLP-1 medications appear to compound that pre-existing risk.

How serious were these cases?

The severity figures are sobering. Among the 1,829 adverse event reports:

• 92% were classified as serious outcomes
• 49.9% resulted in hospitalisation
• A significant proportion required cholecystectomy (gallbladder removal surgery)

These are not mild inconveniences. Gallbladder disease requiring hospitalisation means acute cholecystitis (infected gallbladder), severe cholelithiasis (gallstones causing bile duct blockage), or biliary colic severe enough to need intervention. The 92% serious outcome rate suggests that when GLP-1-associated gallbladder disease develops, it tends to develop acutely rather than as a slowly progressive asymptomatic condition.

Which drug carries the highest risk?

The signal strength varied significantly by drug. Using reporting odds ratio (ROR) as the primary measure, with values above 1.0 indicating a positive signal:

• Liraglutide: ROR 6.75 (95% CI: 6.17-7.38) - strongest signal
• Semaglutide: ROR 5.74 (95% CI: 5.24-6.28)
• Exenatide: ROR 1.88 (95% CI: 1.72-2.05)
• Tirzepatide: ROR 1.98 (95% CI: 1.70-2.32)
• Dulaglutide: ROR 1.29 (95% CI: 1.12-1.49) - weakest signal

Liraglutide (Saxenda, Victoza) carries the highest pharmacovigilance signal - nearly seven times the reporting rate expected by chance. Semaglutide (Ozempic, Wegovy, Rybelsus) is close behind at 5.7x. Tirzepatide (Mounjaro, Zepbound) sits at about 2x - still a positive signal, but notably lower than the longer-established GLP-1 mono-agonists.

One important caveat: exenatide has been on the market much longer than tirzepatide, so its lower ROR partly reflects a more diluted denominator. Tirzepatide's ROR may increase as more long-term reports accumulate.

How quickly does gallbladder disease develop?

The median time from starting a GLP-1 medication to developing gallbladder disease was 182 days overall - just under six months. But this varied dramatically by drug:

• Tirzepatide: shortest onset at a median of 80 days
• Exenatide: longest onset at a median of 230 days
• Liraglutide and semaglutide: around 160-180 days

Tirzepatide's faster onset is worth noting. The dual GLP-1 and GIP agonism in tirzepatide drives more rapid and significant weight loss than GLP-1 mono-agonists. Rapid weight loss is itself a major trigger for gallstone formation - bile becomes supersaturated with cholesterol when fat is mobilised quickly, and slower gallbladder emptying (a direct GLP-1 effect) prevents that cholesterol from being cleared. The combination creates ideal conditions for stone formation.

Who is most vulnerable?

Several factors significantly increase gallbladder disease risk in GLP-1 users:

• Female sex - especially post-menopausal; oestrogen increases cholesterol saturation of bile
• Age over 45
• Obesity at baseline - higher cholesterol load in bile
• Rapid weight loss - mobilises fat quickly and concentrates bile
• Pre-existing metabolic dysfunction-associated steatotic liver disease (MASLD)
• Type 2 diabetes with insulin resistance
• Personal or family history of gallstones

If you fall into multiple of these categories, proactive monitoring makes sense. The symptoms of gallbladder disease in GLP-1 users can mimic GI side effects from the medication itself - nausea, right upper abdominal discomfort, bloating after fatty meals - which makes it easy to attribute early gallbladder warning signs to the medication's expected GI effects rather than investigating further.

What to watch for

Seek prompt medical attention if you experience any of the following while on GLP-1 medications:

• Sudden, severe pain in the right upper abdomen or right shoulder blade area
• Pain that worsens after eating fatty meals
• Nausea and vomiting accompanied by abdominal pain (distinct from the nausea you notice shortly after injecting)
• Fever alongside abdominal pain - a sign of potential gallbladder infection
• Jaundice (yellowing of skin or eyes) - suggests a stone in the bile duct

Routine abdominal ultrasound screening is not currently recommended for all GLP-1 users - the absolute risk remains modest even with the elevated relative risk. But for high-risk patients (women over 45 with obesity, rapid weight loss, or a prior gallstone history), discussing baseline imaging with your prescriber is a reasonable conversation. GLP-1 Shield is formulated to support overall GLP-1 nutritional needs - while it does not directly address gallbladder risk, supporting healthy digestion and bile flow through adequate magnesium intake is part of a comprehensive approach to GLP-1 health.

Frequently asked questions

Do GLP-1 medications cause gallstones?

Yes, GLP-1 medications are associated with increased gallstone risk. This study confirms a positive pharmacovigilance signal for all five major GLP-1 drugs in real-world data. The mechanism involves GLP-1 slowing gallbladder emptying, which allows cholesterol to concentrate in bile and crystallise into stones. Rapid weight loss - a consequence of GLP-1 use - further concentrates bile and raises stone formation risk.

Which GLP-1 medication is most likely to cause gallbladder problems?

Based on FAERS data, liraglutide carries the strongest pharmacovigilance signal (ROR 6.75), followed by semaglutide (ROR 5.74). Tirzepatide and exenatide show lower signals but are still positive. Tirzepatide has the fastest onset at a median of 80 days - possibly because it drives faster weight loss than mono-agonists. The lowest signal was for dulaglutide (Trulicity).

Is gallbladder disease from GLP-1 medications serious?

92% of FAERS reports were classified as serious outcomes, and nearly half resulted in hospitalisation. When GLP-1-associated gallbladder disease develops, it typically presents acutely rather than as a slow, asymptomatic process. This is why recognising the warning symptoms - severe right upper abdominal pain, pain worsening after fatty meals, fever - and seeking prompt medical attention matters.

What are the symptoms of gallbladder problems on Ozempic or Wegovy?

Symptoms include sudden severe right upper abdominal pain (often radiating to the right shoulder blade), nausea and vomiting with abdominal pain, pain after fatty meals, fever, and in severe cases, jaundice. These can be confused with GLP-1 GI side effects early on. The key distinguishing feature is the location and severity of pain - gallbladder pain is sharper and more localised than typical GLP-1 nausea.